

Kisunla (donanemab-azbt)

Provider Order Form rev. 1/2/2026



PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Full Name: _____ DOB: _____ Phone: _____ Gender: ☐ M ☐ F ☐ Other

Email Address: _____ Address: _____ Weight (lbs/kg): _____ Height (in): _____

☐ NKDA Allergies: _____ Existing prior authorization? ☐ Yes, (Send a copy) ☐ No (AIC will process)

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

Patient Preferred Location: _____

DIAGNOSIS & CLINICAL INFORMATION

ICD 10-Code & Description

- ☐ G30.0 Alzheimer's disease with early onset
☐ G30.1 Alzheimer's disease with late onset
☐ G30.8 Other Alzheimer's disease, unspecified
☐ G31.84 Mild Cognitive impairment of uncertain or unknown etiology
☐ Other: _____

If using CMS-approved clinical trial or registry PLEASE SELECT alongside primary diagnosis code:

- ☐ Z00.6 (encounter for examination for normal comparison and control in clinical research study)

REQUIRED DOCUMENTATION: Please include insurance card (front & back), all patient demographics, history & physicals, medication lists, recent lab results (CBC, CMP, TB, Hep B panel-depending on medication), signed prescription order and recent visit notes.

Confirm that these and the required lab orders have been sent to American Infusion Care and necessary parties.

PRESCRIPTION INFORMATION

Nursing: Provide nursing care per American Infusion Care - Specialty Infusions protocols, including reaction management and post-procedure observation

Pre-Medications

- ☐ Acetaminophen (Tylenol) ☐ 500mg ☐ 650mg ☐ 1000mgPO
☐ Cetirizine (Zyrtec) 10mgPO
☐ Loratadine (Claritin) 10mgPO
☐ Diphenhydramine (Benadryl) ☐ 25mg ☐ 50mg ☐ PO ☐ IV
☐ Methylprednisolone (Solu-Medrol) ☐ 40mg ☐ 125mg IV
☐ Other: _____ Dose: _____ Route: _____

****MRIs should be performed at baseline & prior to the 2nd, 3rd, 4th and 7th infusion**

Lab Orders

- Required:** TB test results, MRI within 1 year
Cognitive Assessment Score _____
Confirmed presence of amyloid pathology
CMS Registry confirmation ALZH _____ (medicare and medicare advantage only)
ApoE ε4 Testing (if available)
Patient has been provided ARIA Risk Counseling
☐ Other: _____

Kisunla (donanemab-azbt) (Select one):

☐ Standard dosing

Infusion 1: Infuse 350 mg IV x1

Infusion 2: Infuse 700 mg IV x 1, 4 weeks after Infusion 1

Infusion 3: Infuse 1050 mg IV x1, 4 weeks after Infusion 2

Infusion 4 and beyond: Infuse 1400 mg IV every 4 weeks, beginning 4 weeks after Infusion 3

☐ Other: _____

****Medication will be infused over approximately 30 minutes.**

****Using a 50ml 0.9% Sodium Chloride IV bag, flush IV tubing with NS 10 to 20 mL after each infusion.**

☐ Refills: ☐ zero ☐ 6 months ☐ 12 months ☐ _____ (Prescription valid for one year, unless otherwise indicated)

Post Treatment Observations: The patient is required to stay for 30 minutes following the first administration.

Special Instructions: _____

PROVIDER INFORMATION

Provider Full Name: _____ Provider NPI #: _____ Specialty: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____

Provider Name (Print)

Provider Signature

Date

E: Referrals@americaninfusioncare.com
Americaninfusioncare.com

Greater Houston Area F: 832.510.7824 P: 832.800.3213
McAllen F: 956.302.8906 P: 832.800.3213 Plano: F: 214.831.9829 P: 972.865.4454
Harlingen F: 956.341.9687 P: 832.800.3213 Laredo F: 956.306.3715 P: 832.800.3213
Other Locations (Oaklawn, Lancaster, etc): F: 469.305.2361 P: 972.865.4454